AstraZeneca’s IL‑33 biologic Tozorakimab hits multiple Phase III successes – Meet them this September

Altesa BioSciences advances Vapendavir for rhinovirus‑triggered COPD exacerbations

GSK expands its COPD pipeline with a novel siRNA therapy (EMP‑012)

Emerging COPD treatments highlight biologics, bronchoscopic procedures & stem‑cell approaches

ReAlta’s pegtarazimod showing early promise for acute COPD exacerbations in phase 2

GSK’s Nucala gains UK backing, expanding COPD biologic access with NICE recommendation

Windward Bio and Harbour Biomed announce first Phase II dosing in SIRIUS trial for novel COPD antibody therapy

TidalSense secured $19 million to commercialise its AI-powered COPD diagnostic technology

Day

Hour

Minute

Second

AI-Based Mucus Analysis: From Automated Quantification at Scale to Multidimensional Patient Phenotyping, Treatment Response & Disease Progression Monitoring

2:00 pm - Tuesday 15th September 2026

How does fully automated AI enable reproducible mucus plug assessment across large cohorts, and what does validation in real-world COPD and other lung disease data tell us about its robustness?
How can mucus analysis, combined with complementary structural CT metrics, better characterize COPD heterogeneity and patient phenotypes?
How can sensitive quantitative CT measurements detect subtle changes over time to assess early treatment response and advance disease progression prediction?

Harm Tiddens

Chief Medical Officer

Thirona Bio